Document is current

Article History

Received: 5 May 2022

Accepted: 4 June 2023

First Online: 13 June 2023

Declarations

:

: The study was registered at ClinicalTrials.gov, identifier NCT04389541, and received a positive consultation result by the Ethics Committee of the Landesärztekammer Baden-Württemberg, as well as local ethics committees of the participating physicians, if required, before start of patient enrollment. The study is conducted in accordance with the principles of the Declaration of Helsinki and all patients alive at the time of study registration provide written informed consent prior to inclusion into the study.

: Not applicable.

: UM reports grants from the Dieter Schwarz Foundation; consulting fees by BMS, Sanofi, Pierre Fabre, and Roche; honoraria for lectures / presentations / manuscript writing by BMS; support for attending meetings and / or travel by Lilly, Amgen, Roche, BMS, and Pierre Fabre; participation on an Advisory Board for iOMEDICO; Chairmanship of Cancer Society Baden-Württemberg. JS reports support for the present manuscript by iOMEDICO; consulting fees by MSD; honoraria for lectures / presentations / manuscript writing by MSD; support for attending meetings and / or travel grants by Octapharm, GSK, and Ipsen; participation on a Data Safety Monitoring Board / Advisory Board for MSD, and Organon; honoraria from iOMEDICO, Celgene, Roche, Bristol-Myers Squibb, Clovis Oncology GmbH, GSK, Boehringer Ingelheim, Amgen, Novartis, MSD, AOP, Searchlight, Pharma Partner, Medixline GmbH, Eisai, HE Research GmbH, Octapharma, AbbVie, NIO, I+E Research, and Ipsen; membership of scientific organizations: Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Hämatalogie und Onkologie, European Society of Medical Oncology, BNHO – Berufsverband der Niedergelassenen Hämatologen und Onkologen, WINHO – Wissenschaftliches Institut der Niedergelassenen Hämatologen und Onkologen, AKS – Arbeitskreis klinische Studien in onkologischen und hämatologischen Praxen, ASCO – American Society of Clinical Oncology. MZ reports honoraria for lectures / presentations / manuscript writing by Novartis, Roche, and Vifor; participation on a Data Safety Monitoring Board or Advisory Board by AbbVie, BMS, Celgene, Janssen, Novartis, Roche, and Vifor. TD reports participation on a Data Safety Monitoring Board / Advisory Board for Novartis as well as Steering Board participation for iOMEDICO. AS reports research grants from Celgene and Roche; honoraria from Amgen, AstraZeneca, Aurikamed, Bayer, Celgene, Clinsol, Connectmedica, Gilead, GSK, I-MED, Lilly, MCI Deutschland, Metaplan, MSD, Nanostring, Novartis, Onkowissen.de, Promedicis, Pfizer, Pierre Fabre, Roche, Seagen, Streamedup, Teva, Tesaro and Thieme; travel support from Celgene, Pfizer, and Roche. MS reports compensation for consultant activities by Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Roche, Sanofi, and Takeda; honoraria for CME presentations by Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, and Novartis; research funding to institution by AstraZeneca and Bristol-Myers Squibb. NM reports grants for trials and registries by Roche; Advisory Board consulting fees by Roche; honoraria for presentations by Roche, MSD, Eisai, and Lilly; travel grants by Roche. BK reports consulting fees by Astellas and Roche; Biontech stocks. FB, LS, SB, SFG, SG, SZ, KP, and CV declare that they have no competing interests.